{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:45:20Z","timestamp":1764225920732,"version":"3.46.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Progressive familial intrahepatic cholestasis (PFIC) are rare genetic hepatocellular disorders that affect bile secretion and predominantly manifest in early childhood. PFIC2, which is caused by mutations in the ABCB11 gene, often progresses to end-stage liver disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present the case of a male infant with PFIC2, which was associated with a heterozygous frameshift mutation in the ABCB11 gene as well as an additional heterozygous variant in the ATP8B1 gene. Initial clinical management involved ursodeoxycholic acid (UDCA) administration and fat-soluble vitamin supplementation. However, it was only after switching treatment to the ileal bile acid transporter (IBAT) inhibitor odevixibat at three months of age, that the patient exhibited significant improvement, including normalization of cholestasis parameters and liver enzymes. Liver function has remained stable on therapy for 2.5 years during which time the patient has maintained normal growth and development with no evidence of disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case study highlights the effectiveness of odevixibat in managing PFIC2, demonstrating sustained disease suppression and symptomatic relief. It also emphasizes the importance of comprehensive clinical evaluation and accurate disease characterization as well as the potential of targeted therapies in improving outcomes for patients with PFIC2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1648663","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:31:10Z","timestamp":1764225070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Sustained biochemical remission following early initiation of odevixibat in an infant with monoallelic ABCB11 mutation and histologically confirmed PFIC2"],"prefix":"10.3389","volume":"13","author":[{"given":"Thomas","family":"Kehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Thomas","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Evert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren","family":"Zapke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Woelfle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Melter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Hoerning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"104317","DOI":"10.1016\/j.ejmg.2021.104317","article-title":"The spectrum of progressive familial intrahepatic cholestasis diseases: update on pathophysiology and emerging treatments","volume":"64","author":"Felzen","year":"2021","journal-title":"Eur J Med Genet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinre.2018.07.010","article-title":"Systematic review of progressive familial intrahepatic cholestasis","volume":"43","author":"Baker","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/HMER.S137209","article-title":"Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment","volume":"10","author":"Gunaydin","year":"2018","journal-title":"Hepat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jpeds.2021.09.019","article-title":"Kif12 variants and disturbed hepatocyte polarity in children with a phenotypic spectrum of cholestatic liver disease","volume":"240","author":"Stalke","year":"2022","journal-title":"J Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jhep.2020.02.007","article-title":"Genotype correlates with the natural history of severe bile salt export pump deficiency","volume":"73","author":"van Wessel","year":"2020","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cld.872","article-title":"Inherited cholestatic diseases in the era of personalized medicine","volume":"15","author":"Goldberg","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (march-pfic): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jceh.2013.10.005","article-title":"Progressive familial intrahepatic cholestasis","volume":"4","author":"Srivastava","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"B11","volume-title":"S2k-Leitlinie Cholestase Im Neugeborenenalter, Awmf-Register Nr. 068\/015, Stand: 08\/2020","author":"Grothues","year":"2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fped.2015.00043","article-title":"Neonatal cholestasis\u2014differential diagnoses, current diagnostic procedures, and treatment","volume":"3","author":"G\u00f6tze","year":"2015","journal-title":"Front Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fped.2014.00065","article-title":"Diversity of disorders causing neonatal cholestasis\u2014the experience of a tertiary pediatric center in Germany","volume":"2","author":"Hoerning","year":"2014","journal-title":"Front Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100626","DOI":"10.1016\/j.jhepr.2022.100626","article-title":"Genotype-Phenotype relationships of truncating mutations, P.E297g and P.D482g in bile salt export pump deficiency","volume":"5","author":"Felzen","year":"2023","journal-title":"JHEP Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101309","DOI":"10.1016\/j.jhepr.2024.101309","article-title":"Real-world experience with odevixibat in children with progressive familial intrahepatic cholestasis","volume":"7","author":"Di Giorgio","year":"2024","journal-title":"JHEP Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/hep.23539","article-title":"Atp8b1 and Abcb11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (pfic): phenotypic differences between Pfic1 and Pfic2 and natural history","volume":"51","author":"Davit-Spraul","year":"2010","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/PAS.0b013e318212ec87","article-title":"Morphologic findings in progressive familial intrahepatic cholestasis 2 (Pfic2): correlation with genetic and immunohistochemical studies","volume":"35","author":"Evason","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1053\/j.gastro.2008.01.038","article-title":"Severe bile salt export pump deficiency: 82 different Abcb11 mutations in 109 families","volume":"134","author":"Strautnieks","year":"2008","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.3390\/jcm13247508","article-title":"Practical considerations for odevixibat treatment in patients with progressive familial intrahepatic cholestasis: a single-center case series","volume":"13","author":"Marx","year":"2024","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1061535","DOI":"10.3389\/fped.2023.1061535","article-title":"Case report: add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis","volume":"11","author":"Pepe","year":"2023","journal-title":"Front Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102185","DOI":"10.1016\/j.clinre.2023.102185","article-title":"Treatment with an ileal bile acid transporter inhibitor in patients with Tjp2 deficiency","volume":"47","author":"Di Giorgio","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e234185","DOI":"10.1136\/bcr-2019-234185","article-title":"Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis","volume":"13","author":"Slavetinsky","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100782","DOI":"10.1016\/j.jhepr.2023.100782","article-title":"Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis","volume":"5","author":"Thompson","year":"2023","journal-title":"JHEP Rep"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1648663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:31:21Z","timestamp":1764225081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1648663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":23,"alternative-id":["10.3389\/fped.2025.1648663"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1648663","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1648663"}}